The DOI matches its Crossref record.
Severe Hepatocellular Dysfunction following Cyproterone Acetate Therapy
Abstract
Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. Although it is generally well tolerated, liver toxicity has been recognised as a complication of long-term use. We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CPA has been associated with fatal liver toxicity.
“CPA has been associated with fatal liver toxicity (Parys 1991; Roila 1993).”
From Pharmacological interventions for those who have sexually offended or are at risk of offending (2015) · cites this paper as Parys 1991
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 4
- Huggins, 1941, Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res., 1, 293
- Herbst, 1941, Effects of estradiol propianate and diethylstilbestrol on malignant prostatic tissue, Trans. Am. Assoc. Genitourin. Surg., 34, 195
- Levesque, 1989, Fulminant hepatitis due to cyproterone acetate, Lancet, 1, 215, 10.1016/S0140-6736(89)91225-7 · DOI
- Meijers, 1986, Hepatocellular damage by cyproterone acetate, Eur. J. Cancer Clin. Oncol, 22, 1121, 10.1016/0277-5379(86)90017-9 · DOI
Cited by
Sorted by citations
Pharmacological interventions for those who have sexually offended or are at risk of offending
Khan, O., Ferriter, M., Huband, N., Powney, M. J., Dennis, J. A., & Duggan, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007989.pub2 · Cited by 144
Cyproterone acetate: hepatoxicity and prostatic cancer treatment
Roila, F., Crinò, L., Carloni, G., & Natalini, G. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058631 · Cited by 19
Metadata
- Authors
- PARYS, B. T., HAMID, S., & THOMSON, R. G. N.
- Affiliations
- Royal Preston Hospital (GB)
- Corresponding author
- PARYS, B. T.
- ORCID
- HAMID, S.
- Venue
- British Journal of Urology
- Publisher
- Wiley
- Published
- 1991-03
- Volume
- 67
- Issue
- 3
- Pages
- 312-313
- ISSN
- 1464-4096 (ISSN-L)
- 0007-1331
- 1464-410X
- OpenAlex
- W2033771600
- Cited by
- 39
- References
- 0
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 1 · 2015: 2 · 2014: 1 · 2012: 2
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- cyproterone acetate, hepatotoxicity, hepatocellular dysfunction, fulminant hepatitis, advanced prostate cancer, drug-induced liver injury, adverse drug reactions
- MeSH terms
- Aged, Aged, 80 and over, Antineoplastic Agents, Cyproterone, Humans, Male, Prostatic Neoplasms, Cyproterone Acetate, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
